Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.
about
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationInflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional toleranceTargeting CD8+ T-cell tolerance for cancer immunotherapy.Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in miceCheckpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytesProgrammed death-1 checkpoint blockade in acute myeloid leukemia.Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.Tolerance and exhaustion: defining mechanisms of T cell dysfunction.Immune evasion in acute myeloid leukemia: current concepts and future directions.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Mechanisms of Immune Tolerance in Leukemia and Lymphoma.Neuropilin-1 expression is induced on tolerant self-reactive CD8+ T cells but is dispensable for the tolerant phenotype.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Monitoring antigen-specific T cell responses using real-time PCR.Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.Tumor immunology: multidisciplinary science driving basic and clinical advances.Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes.The progress and current status of immunotherapy in acute myeloid leukemia.The emerging role of immune checkpoint based approaches in AML and MDS.TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
P2860
Q28068378-8DD53B22-AC40-46CD-BA17-D5F48373B196Q34066709-398EECBA-BFD9-4912-B1FC-C32258BF464EQ34432692-50E30A42-477F-4950-AB93-25887C9837D9Q35064059-50B5E5B3-3C4B-4AB4-85A9-960A08549515Q35071484-70B30EAF-4A80-46A7-A929-96EB27200615Q35151883-106E73B1-207C-443D-BEBD-CB8D36D9B11DQ35483823-5B5FCB77-02F3-4582-B3C4-2AE4F76921B5Q36652124-4D518414-E6B7-4A99-BB23-3A0A8DC60DCBQ38108353-A17D1600-1625-450B-BB5C-0254B4239EC2Q38161101-62DEDAA7-A57C-44C5-8DDE-7D9EDED44DA8Q38172521-ED175645-954C-48B4-A01B-DA4C61723523Q38525024-BF542644-10DB-46D2-804E-4685FB5B36F0Q38683034-CCAB4A8F-4703-4166-A233-0CA7CBF6D32FQ38945311-65E68731-179B-429A-B90C-EAFCE137D618Q39130451-D690463A-515D-48A7-9B3E-0975B4EF0CCCQ40795204-2F92C53A-F82F-41CE-AE35-16BD85054C77Q41537589-EE0FEF1E-A6BE-4384-A5F2-6DE64055EC3CQ41853258-9EB9202B-CCD5-47CF-B42C-DF8C1D122E50Q45163749-F5FBBE75-B307-4CE2-AB89-5F21297CBE31Q47590707-60F0D275-C2AD-48CE-B63B-9ACD5C2538B8Q48173100-5EFC3150-3D3E-4100-AC83-43B72AF41DE4Q52316792-4C753A72-0EE7-4D9F-84A7-1677EB17BCBFQ57483931-BA4269EB-756B-45BD-8EE9-B584274E9A9D
P2860
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Durable adoptive immunotherapy ...... ways of CD8+ T-cell tolerance.
@ast
Durable adoptive immunotherapy ...... ways of CD8+ T-cell tolerance.
@en
type
label
Durable adoptive immunotherapy ...... ways of CD8+ T-cell tolerance.
@ast
Durable adoptive immunotherapy ...... ways of CD8+ T-cell tolerance.
@en
prefLabel
Durable adoptive immunotherapy ...... ways of CD8+ T-cell tolerance.
@ast
Durable adoptive immunotherapy ...... ways of CD8+ T-cell tolerance.
@en
P2093
P2860
P1433
P1476
Durable adoptive immunotherapy ...... ways of CD8+ T-cell tolerance.
@en
P2093
Craig J Rouskey
Hideo Yagita
Jennifer M Meyer
Melissa M Berrien-Elliott
Philip D Greenberg
Richard J DiPaolo
Ryan M Teague
Stephanie R Jackson
Thanh-Long M Nguyen
P2860
P304
P356
10.1158/0008-5472.CAN-12-2179
P407
P577
2012-11-27T00:00:00Z